This is an open label, single arm, multi-centre phase II study to assess the anti-tumour activity and safety of BGB324 in combination with pembrolizumab in up to 48 patients with previously treated advanced adenocarcinoma of the lung. The study will utilise an extension of Simon's 2-stage design. The primary objective is objective response rate.